製薬企業の臨床開発と顧客エンゲージメントにおける課題と今後の論点
製薬企業にとって重要性が高く、かつ、データやテクノロジーを適切に活用することで大きな効果が見込まれる「臨床開発」と「顧客エンゲージメント」の現状とペインポイント、今後考えるべき論点を見ていきます。
製薬企業にとって重要性が高く、かつ、データやテクノロジーを適切に活用することで大きな効果が見込まれる「臨床開発」と「顧客エンゲージメント」の現状とペインポイント、今後考えるべき論点を見ていきます。
日本の将来を考えるにあたり、国民の日々の安心が守られ、必要な革新的医薬品が国民に遅滞なく届くよう、国民皆保険制度を維持しつつ、戦略産業の観点からもイノベーションを推進し、国力を高めることが重要です。医薬品に焦点を当て、日本における課題と議論を整理し、薬価制度、薬事制度といった具体的な取り組みについて考察します。
さまざまな医療機関への経営改善支援の経験を基に、医療の質と生産性をともに高めるための考え方と実践的手法について解説します。経営層と現場が一体となった経営改善活動の推進に向け明日から取り組める打ち手が盛り込まれています。
Dr. Alexandra Bause explains how today’s reactive approach provides sick care, not health care—and how biopharma strives to change that.
Even in a strong market, CROs are facing some longer-term challenges that could reshape the industry in the next five to ten years.
The cash generics market has the potential to become a $15 billion market by 2030. Here’s how incumbents and new entrants should prepare.
New GenAI offerings can benefit virtually every aspect of an organization, boosting efficiency and productivity in areas ranging from R&D to commercial activities.
Manufacturing costs are rising rapidly, with no end in sight. Leaders that balance the various tradeoffs can remain competitive over the long run.
The Team B approach involves assembling an independent cross-functional team to conduct rapid reviews of launch plans and market conditions for new pharmaceutical products.
Biopharma companies can leverage new sources of patient data and technology to create more personalized patient experiences that have the potential to deliver better health outcomes.
グローバルなバイオ医薬品会社のデータ・テクノロジー最高責任者(CDTO)が、バリューチェーン全体にデジタル機能を導入し、患者の治療結果に注力することについて語る。
Mike McDonnell explains how the global biotech is charting new paths to patients via Fit for Growth, its corporate transformation initiative.
Chief Digital and Technology Officer Lidia Fonseca explains how Pfizer is leveraging digital and data across the value chain and the biggest wins so far.
Hudson discusses the company’s commitment to reaching net zero emissions by 2045.
Personalization is a $2 trillion opportunity. BCG's new book offers a playbook for capturing your share of this personalization prize in the health care industry.
Learn More About Personalized
Benchmark Your Personalization Readiness Now
Health care companies can unlock AI's potential and drive sales growth by prioritizing change management—not just technology—says BCG’s Basir Mustaghni.
To thrive during turbulent economic times, health systems can learn from the aviation industry, which embraced novel diversification approaches to maintain revenue stability and improve profitability.
While digital, data, and AI have extraordinary potential to revolutionize our global health care systems, they have yet to deliver a transformative impact. How can the public and private sectors accelerate progress?
The latest technologies hold tremendous promise for health care, but they also pose significant challenges. Not all organizations are prepared to take advantage of the tech trends.
By developing products for a broader base of patients and markets, medtech companies can improve health outcomes, generate business advantages, and contribute to healthier societies overall.
Most environmental waste generated by the health care sector comes from medtech products. For a sector focused on improving quality of life, reducing waste and greenhouse gases is imperative.
To realize the promise and potential for GenAI, medtech executives must make swift and targeted efforts.
Medtech management teams face an unfamiliar list of questions. The players that can successfully navigate the challenging terrain will be the winners of the 2020s.
Extreme weather events such as cyclones and floods will drive increases in the incidence of sickness and death from malaria in Africa, according to a new study.
BCG conducted a study of more than 70 organizations—including philanthropies, multilateral development banks, government agencies, nongovernmental organizations, private sector actors, and others—to understand how key stakeholders are approaching the climate-health challenge.
Too often is it taken for granted that the environment is a massive determinant of human well-being. Putting health at the center of our climate discussions is critical.
The biopharma industry faces demands for more action to address health inequities. We provide a guide and tools to help companies integrate equity across the product lifecycle.